Big opportunities in Asia's emerging pharma markets

The pharmaceutical market in Asia-Pacific has quickly become the focus of global drug companies as they seek to drive growth worldwide. With traditionally strong markets like the USA and Europe stagnating, emerging ones, like those found in China, India, Singapore and Hong Kong, are gaining importance, according to a new report from EyeforPharma.

Market experts agree that success in the region will rely on transferring effective approaches developed in core markets, but adapting them to the diverse needs of local areas within the region, which are all at varying stages of evolution.

Pharmaceutical executives surveyed by EyeforPharma say health care cost containment, competition from generics and increases in codes and regulations are key challenges for companies operating in Asia-Pacific. But the biggest gains, they believe, will come from developing strong drug pipelines and improving the efficiency of their sales forces.